{"id":13210,"date":"2026-05-29T18:22:00","date_gmt":"2026-05-29T16:22:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=008eecc48bb01f40134fc8a53471532f"},"modified":"2026-05-29T18:22:00","modified_gmt":"2026-05-29T16:22:00","slug":"aldx-final-deadline-alert-faruqi-faruqi-llp-reminds-aldeyra-therapeutics-aldx-investors-of-securities-class-action-deadline-on-may-29-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=13210","title":{"rendered":"ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026"},"content":{"rendered":"

\nFaruqi & Faruqi, LLP Securities Litigation Partner <\/b>James (Josh) Wilson<\/b><\/a> Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options<\/b><\/p><\/a><\/a><\/a><\/a>

\nIf you purchased or acquired securities in <\/b>Aldeyra<\/b><\/a> between November 3, 2023 and March 16, 2026 <\/b>and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly <\/b>at 877-247-4292 <\/b>or 212-983-9330 (Ext. 1310)<\/b>.<\/p>

\n[You may also click here for additional information]<\/b><\/a><\/p>

NEW YORK--(BUSINESS WIRE)--$ALDX<\/a> #ALDX<\/a>--Faruqi & Faruqi, LLP<\/a>, a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (\u201cAldeyra\u201d or the \u201cCompany\u201d) (NASDAQ: ALDX) and reminds investors of the May 29, 2026 deadline<\/b> to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.<\/p>

\nFaruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com<\/a>.<\/p>

\nAs detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and\/or misleading statements and\/or failing to disclose that: (1) The results of the reproxalap (an Aldeyra drug candidate) clinical trials were inconsistent; (2) the inconsistency of the results rendered any purported positive findings from these trials unreliable and not meaningful; and (3) as a result, defendants\u2019 statements about Aldeyra\u2019s business, operations, and prospects were materially false and misleading and\/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damage.<\/p>

\nOn March 17, 2026, Aldeyra disclosed that the FDA issued a Complete Response Letter rejecting its NDA for reproxalap, citing insufficient evidence of efficacy. The FDA found that the company\u2019s clinical studies failed to provide adequate, well-controlled support that the drug effectively treats dry eye disease, noting inconsistent results and concluding that the overall data does not demonstrate the product\u2019s effectiveness.<\/p>

\nOn this news, Aldeyra's stock price fell $2.99 \u200b\u200bper share, or 70.7% to close at $1.24 per share on March 17, 2026.<\/p>

\nThe court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.<\/p>

\nFaruqi & Faruqi, LLP also encourages anyone with information regarding Aldeyra\u2019s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.<\/p>

\nTo learn more about the Aldeyra<\/b> class action, go to www.faruqilaw.com\/ALDX<\/b><\/a> or call<\/b> Faruqi & Faruqi partner Josh Wilson directly <\/b>at 877-247-4292 <\/b>or 212-983-9330 (Ext. 1310)<\/b>.<\/p>

\nFollow us for updates on LinkedIn<\/a>, on X<\/a>, or on Facebook<\/a>.<\/p>

\nAttorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com<\/a>). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.<\/p> Contacts<\/b>

\nFaruqi & Faruqi, LLP\nJosh Wilson\n877-247-4292 or 212-983-9330 (Ext. 1310)<\/p>","protected":false},"excerpt":{"rendered":"

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options
\nIf you purchased or acquired securities in Aldeyra between November 3, 2023…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-13210","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13210"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13210\/revisions"}],"predecessor-version":[{"id":13211,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13210\/revisions\/13211"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}